Merck & Co.
MRK · What the business does, what can go wrong, and how options sellers approach it
What it does
Merck & Co. is a global healthcare company that develops, makes and sells prescription medicines, vaccines and animal health products. In most markets outside the US and Canada, it operates as MSD.
Its main areas include cancer treatment, vaccines, infectious disease, cardiometabolic conditions and veterinary medicine. Its best-known products include Keytruda, an immuno-oncology drug, and Gardasil, a vaccine against HPV.
How it makes money
Merck earns revenue by selling patented medicines and vaccines to wholesalers, hospitals, pharmacies, governments and health systems. Its animal health unit sells products for pets and livestock.
Profit depends on pricing, volume and the cost of research. A drug that works well and is protected by patents can be very profitable. Once patents expire, generic competition usually cuts sales sharply.
Why investors own it
- Established franchises: A few large products generate substantial cash flow.
- Dividend: The company has a long record of paying dividends, though they are never guaranteed.
- Diversification: It spans oncology, vaccines and animal health, so it is not tied to one disease area.
- Pipeline: Ongoing research may produce new products to replace aging ones.
What can go wrong
- Patent expiration: Reliance on a few big products makes the loss of exclusivity a major risk.
- Pricing pressure: Governments and insurers in the US and abroad can push drug prices down.
- Clinical and regulatory setbacks: Trials can fail, and approvals can be delayed or denied.
- Policy and trade: Changes in healthcare law, tariffs or international demand can affect results.
- Litigation and safety issues: Product liability claims or safety findings can be costly.
What to watch
- Sales trends for Keytruda and Gardasil
- Patent expiration dates and biosimilar competition
- Clinical trial readouts and regulatory decisions
- Pipeline progress in new drugs and vaccines
- Operating margins and research spending
- Drug pricing legislation and policy changes
- Dividend declarations
Options income angle
Options on MRK are generally liquid, with many strikes and expirations available. Implied volatility tends to be moderate for a large drug maker, but it can rise ahead of earnings, major trial results, regulatory decisions and policy news.
One caution for anyone selling premium: a single clinical or regulatory announcement can cause a sharp price move. A short call can cap gains if the stock jumps, and a short put can lead to a loss if it drops. Dividend dates also matter, since early assignment on short calls can happen around the ex-dividend date.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 24, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Merck reported 2025 sales of $65,011 million, up 1%, with Keytruda alone making up 49% of total sales. The filing shows a company that depends heavily on one cancer drug while several other products lose market exclusivity or face government-set prices from 2026 onward. A sharp drop in Gardasil sales in China also weighed on the year.
How the business did
- Sales rose 1% to $65,011 million (2% excluding foreign exchange). U.S. sales were $36,510 million, up 13%. International sales were $28,501 million, down 11%.
- Keytruda/Keytruda Qlex sales were $31,680 million, up 7%. Welireg rose 41% to $716 million, and Winrevair reached $1,443 million. Gardasil/Gardasil 9 fell 39% to $5,233 million, mainly on lower demand in China.
- GAAP net income was $18,254 million, up 7%, or $7.28 per diluted share. Non-GAAP net income, which strips out items such as acquisition and restructuring costs, was $22,513 million, up 16%. Gross margin was 74.8% versus 76.3% in 2024, partly on higher restructuring costs and vaccine inventory write-downs.
- Cash provided by operating activities was $16.5 billion versus $21.5 billion in 2024. Management cited higher income tax payments of $6.1 billion and larger upfront and milestone payments. The company returned $13.3 billion to shareholders: dividends of $8.2 billion and share repurchases of $5.1 billion.
- Januvia/Janumet sales grew 12%, driven by higher net pricing, including a favorable true-up to customer discounts. Koselugo alliance revenue included a $150 million upfront payment and $175 million of milestones from an amended AstraZeneca agreement.
Risks specific to this company
- Keytruda dependence. Biosimilar competition could begin in December 2028 when the primary compound patent expires. Merck also expects Keytruda to be selected in 2027 for Medicare price setting under the Inflation Reduction Act (IRA), with the price effective January 1, 2029, and expects U.S. sales to decline materially afterward.
- Near-term exclusivity losses. Januvia and Janumet lose U.S. exclusivity in May 2026, and the company anticipates losing nearly all U.S. sales of both. Bridion loses it in July 2026, and the company expects to discontinue U.S. Bridion sales by the end of 2026.
- China vaccine slump. Gardasil shipments to China were paused beginning in February 2025 and have not resumed, because the distribution partner holds above-normal inventory. The company expects China sales will not materially increase in 2026, and a local nine-valent HPV vaccine was approved in China in June 2025.
- Government pricing. In December 2025 Merck signed a three-year agreement with the U.S. government. It covers direct-to-patient pricing, Medicaid discounts, and "most-favored-nation" pricing (tied to prices in other developed countries) for new launches.
- Tax dispute. The IRS proposed adjustments that would increase a one-time transition tax by approximately $1.3 billion, plus penalties of approximately $260 million. The company disagrees and will contest them.
- Self-insured liability. Merck has no insurance for most product liabilities, and the filing names Gardasil litigation among its legal matters.
What management is watching
- Cidara acquisition. The deal closed in January 2026 for approximately $9.0 billion of expected research charges, or approximately $3.65 per share, in the first quarter of 2026. It adds a long-acting influenza preventive.
- Pipeline breadth. Approximately 80 Phase 3 studies are underway. Oncology work is organized around immuno-oncology, precision molecular targeting and tissue targeting, and the oral cholesterol drug enlicitide decanoate is in Phase 3.
- Cost program. The 2025 Restructuring Program carries cumulative pretax costs of approximately $3.0 billion and is expected to save approximately $1.7 billion annually by the end of 2027. It is part of a wider initiative targeting $3.0 billion in annual savings, to be fully reinvested.
- Investment and capital return. Merck plans approximately $20 billion of capital projects from 2025-2029. The quarterly dividend rose to $0.85 per share from $0.81, and $7.3 billion of repurchase authorization remained at year-end.
- Measures pointed to. Management highlights non-GAAP income and EPS, which also factor into executive pay. It expects Lagevrio sales to keep declining in 2026.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Merck's third-quarter sales grew, led by Keytruda, Winrevair and Welireg, but reported profit fell. Nine-month income before taxes was $1,342 million, down from $17,647 million a year earlier, mainly because Merck expensed large charges for buying experimental drug developers. The filing also points to U.S. generic competition for Januvia, Janumet and Bridion and to price-setting rules ahead.
How the business did
- Sales: Third-quarter sales were $18,085 million, up 5%, and nine-month sales were $50,978 million, up 5%. U.S. sales in both periods benefited by approximately $550 million from the timing of customer purchases. Keytruda/Keytruda Qlex reached $8,601 million (up 6%) in the quarter. Winrevair rose 93% to $694 million and Welireg rose 56% to $307 million.
- Declines: Januvia/Janumet fell 39% to $380 million after losing U.S. market exclusivity (generics entering). Bridion fell 67% to $144 million after generics arrived in July 2026. Lagevrio fell 88% to $17 million.
- Profit: Income before taxes was $5,559 million, compared with $6,745 million a year earlier. Per-share earnings under standard accounting rules (GAAP) were $2.04, compared with $2.32. Gross margin was 72.9%, compared with 77.7%, on higher amortization of acquired intangibles, restructuring costs and production costs.
- Acquisition charges: The Cidara deal produced a $9.0 billion R&D charge and Terns a $5.7 billion charge, both in the first nine months. Both were bought-in unapproved drugs, so the cost was expensed immediately. Neither charge had a tax benefit, so the nine-month effective tax rate was 138.2%.
- Cash: Operating cash flow was $15.8 billion in the nine months, compared with $13.6 billion. Merck paid $6.3 billion in dividends and bought back $2.3 billion of stock. Cash and investments were $11,253 million, compared with $15,521 million at December 31, 2025.
What management is watching
- Timing reversals: The Keytruda wholesaler inventory increase and the Winrevair purchase timing benefit are both expected to unwind in the fourth quarter of 2026. Most of the U.S. Gardasil benefit from public sector purchasing is expected to unwind in 2027.
- Pricing pressure: Government-set prices for Janumet and Janumet XR take effect January 1, 2027. Merck expects Keytruda to be selected for price setting in 2027, effective January 1, 2029. Germany's new health care law, mostly effective January 1, 2027, is expected to put significant downward pressure on revenue there, particularly for Keytruda.
- Spending and capital return: Merck expects to repurchase approximately $3.0 billion of shares in 2026. Its 2025 restructuring program carries estimated cumulative pretax costs of approximately $3.0 billion and expected annual savings of approximately $1.7 billion, substantially realized by the end of 2027.
- Measures cited: Management points to non-GAAP income and EPS, which strip out acquisition-related costs, restructuring and equity investment gains. Non-GAAP EPS was $2.49, compared with $2.58. For the nine months it was $1.08, compared with $6.93.
Follow MRK in Kortex
The Kortex app shows MRK's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.